CBER: new approaches to biological product testing

Area of Science:

• Biotechnology
• Regulatory Science
• Virology

Background:

• Biological products are complex, posing unique testing challenges.
• Method validation for regulatory purposes has specific requirements.
• Animal testing for biological products is subject to policy changes.

Purpose of the Study:

• To discuss recent CBER policy initiatives affecting animal testing for biological products.
• To present the MAPREC test for polio virus neurovirulence as an alternative testing example.
• To provide general insights into the method validation process for biological products.

Main Methods:

• Review of CBER policy initiatives.
• Exposé of the MAPREC test for polio virus neurovirulence.
• Discussion of alternative test development and validation.

Main Results:

• Recent CBER policies impact the use of animal tests.
• The MAPREC test serves as a model for alternative test validation.
• General principles of validation are applicable to biological product testing.

Conclusions:

• Navigating regulatory expectations for biological product testing requires understanding policy and validation.
• Alternative methods like MAPREC are crucial for modernizing safety assessments.
• Robust validation is key to ensuring the safety and efficacy of biological products.